Skip to main content
Lancaster Resources Inc. logo

Lancaster Resources Inc. — Investor Relations & Filings

Ticker · LCR ISIN · CA51440M1023 CSE Mining and quarrying
Open in API
Filings indexed 221 across all filing types
Latest filing 2021-03-11 Regulatory Filings
Country CA Canada
Listing CSE LCR

About Lancaster Resources Inc.

https://lancaster-resources.com/

Lancaster Resources Inc. is a mineral exploration company dedicated to discovering and developing high-potential precious metal and critical mineral assets. The company focuses on gold, lithium, uranium, and polymetallic deposits across established mining jurisdictions, including North America and Australia. Key projects include the Lake Cargelligo Gold Project in New South Wales, Australia, and the Trans-Taiga Lithium Pegmatite Project and Lac Iris Polymetallic Property in Quebec. Lancaster emphasizes advancing projects responsibly with a commitment to sustainable environmental practices and long-term value creation.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing NeonMind Biosciences' engagement with Certara to advance its synthetic psilocybin drug candidates for obesity. It discusses the company's drug development plans, intellectual property, and strategic partnerships. There are no financial statements, regulatory filings, voting results, or management changes. The content is primarily a corporate announcement about a business development initiative rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2021-03-11 English
News release - English.pdf
Regulatory Filings
2021-03-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of four additional provisional patents related to psilocybin preclinical data by NeonMind Biosciences Inc. It discusses intellectual property, patent applications, and preclinical trial data but does not contain any financial statements, earnings data, or regulatory filings related to financial performance. It is not an annual report, earnings release, or any form of financial or regulatory filing. It is also not related to management changes, voting results, or capital structure updates. The content is focused on intellectual property and patent filings, which is typically communicated via press releases or regulatory announcements. Given the nature and length of the document (7,131 characters), it is a regulatory announcement about patent filings rather than a financial or management report. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2021-03-02 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing NeonMind Biosciences' purchase of GMP grade synthetic psilocybin for a planned phase 2 human clinical trial. It discusses the company's research plans, supply agreements, and background information about the companies involved. There are no financial statements, regulatory filings, voting results, or management changes. The document is a corporate announcement about a business development related to clinical trials and product supply, not a financial report or regulatory filing. It is not an earnings release, annual report, or any other formal filing type. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-02-24 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that NeonMind Biosciences Inc. has engaged North Equities for social media marketing services. It contains no financial data, no regulatory form references, no meeting or voting information, no financial results, and no legal or governance details. It is a corporate announcement about a marketing contract, not a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-02-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that NeonMind Biosciences Inc. has submitted applications to Health Canada for product licenses related to natural health products. It discusses the company's product development, regulatory submission status, and future plans. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory announcement about product licensing and business updates rather than a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and business update that does not fit other specific categories.
2021-02-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.